Publications
MIXiii-Biomed 2019: Call for company presentations
1 WEEK LEFTTO SUBMIT YOUR COMPANY PRESENTATION This could be your opportunity to showcase your company’s product and expertise to the local and international
MIXiii-Biomed 2019: one week left to apply for the Start Up pavilion
One week left to submit your application for the Start-Up Pavilion Application deadline: March 14, 2019 Every day 15 new Start-Up companies will present their cutting
MIXiii-Biomed 2019 – Hogan Lovells Invitation
A Satellite Symposium hosted by Hogan LovellsMay 15, 2019 12:00 – 13:30 pmHall D, David InterContinental HotelOur Speakers: Jonathan KahanPartner, FDA Regulatory John J. Smith,
MIXiii-Biomed 2019 – Invited Speakers (Preliminary list)
MIXiii-Biomed 2019 is proud to introduce to you our preliminary list of distinguished, local and international, invited speakers and track chairs. This premiere event is
MIXiii-Biomed 2019: Daily Tracks
MIXiii-Biomed Israel is once again gearing up for an exciting three-day conference. Join us from May 14-16, and find out about the latest information in
MIXiii-Biomed 2019 Call for Start Ups
During May 14-16, 2019, MIXiii-Biomed and Israel Innovation Authority are once again providing the sought-after opportunity for early-stage start-ups to project their companies into the
BIOMED Event In The Press
See MIXIII Biomed in the news around the world.
Israel Innovation Authority, Mayo Clinic set up joint healthcare program
Israeli startups will be able to develop and test their health technologies and medical devices with the Rochester, Minnesota-based institution By SHOSHANNA SOLOMON | 15 May
Israel’s life sciences firms said to raise record $1.5 billion in 2018
Startup Nation’s 1,600 life sciences firms employ 83,000 workers, according to report By SHOSHANNA SOLOMON | Times of Israel Israel is host to some 1,600 life
Israeli startup seeks to boost bone renewal and allow targeted drug delivery
New peptide developed by Bone Sci Bio has shown in clinical trials to be effective in regeneration and integration with existing bone tissue; FDA still
LIFE SCIENCES INNOVATION EMERGES AS KEY AREA OF UK-ISRAEL COLLABORATION
Attending the three-day conference are 11 leading British healthcare organizations, currently collaborating with the British Embassy in Israel to build new innovation partnerships with Israel.
Annual Biomed Confab Highlights Role Of Advanced Tech In Rehabilitation
By Simona Shemer| NoCamels | May 13, 2019 Israel’s annual Mixiii-Biomed conference, the prestigious three-day life science and biomed event now in its 18th year, is kicking
9 devices that could revolutionize current treatments
Heart failure, kidney disease, sleep apnea, diabetes, back pain – disruptive medical devices emerging from Israel could transform treatment for these conditions. By Abigail Klein Leichman
Latest Publications in the field
Find out the latest publications, innovations and news in the field of ophthalmology. To receive the latest news in the field, join our Linkedin group.
FDA clears Pluristem radiation treatment for emergency use
Tova Cohen | Reuters Biologists work in a laboratory at Pluristem Therapeutics in Haifa. A laboratory worker removes cells from a storage unit at Pluristem
United Therapeutics pens $216M deal to buy SteadyMed, neutralizing pump-based threat to PAH franchise
by Nick Paul Taylor | FierceBiotech | Apr 30, 2018 SteadyMed’s pump technology. (SteadyMed) United #Therapeutics has struck a $216 million deal to buy #SteadyMed. The acquisition enables United
Measuring glucose without need for finger-prick blood test
Scientists at Bath University have developed a wearable sensor that measures glucose levels through the skin, an advance that could mark the end of
Israeli Medical Device Developer V-Wave Raises $70 Million
V-Wave develops a minimally #invasive #implanted #shuntdevice for treating patients with severe #heartfailure Meir Orbach | 26.04.18 | CTech Israeli #medical shunt #developer V-Wave Ltd. announced on
Eloxx Pharmaceuticals raises $50m on Nasdaq
News| Globes The company is developing a drug for treatment of cystic fibrosis. Eloxx Pharmaceuticals, which develops drugs for rare genetic diseases, announced that it
U.S. FDA Clears Pluristem’s Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery
Multinational study expected to include clinical sites in U.S. Israel and Europe, where study has been awarded an $8.7 million grant from European Horizon 2020